Decision Modeling to Inform Decision Making: Seeing the Wood for the Trees

Goldman L. , Gaspoz J. -M. Cost-effectiveness of clopidogrel: seeing through the smoke. Med Decis Making. 2008;28:803-9

Karnon J. , Brennan A. , Akehurst R. A critique and impact analysis of decision modeling assumptions. Med Decis Making. 2007; 27:491-9.

Gaspoz JM , Coxson PG , Goldman PA , et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002;346:1800-6.

Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (Version 4.3), 2008. Available from: URL: http://www.pbs.gov.au/html/industry/static/how_to_list_on_the_pbs/elements_of_the_listing_process/pbac_guidelines/b_part_2

National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal (reference N0515), 2004. Available from: URL: http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf

McCabe C. Guidance on good practice in cost-effectiveness modeling: is more needed? Med Decis Making. 2007;27:350-1.

Birkett DJ , Mitchell AS , McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff. 2001;20:104-14.

Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? Can Med Assoc J. 2002;166:44-7.

National Institute for Clinical Excellence (NICE). Bortezomib monotherapy for relapsed multiple myeloma . NICE Technology Appraisal Guidance, October 2007.

Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics. 2006;24(11):1157-62.